Ascendia

  MARKET NEWS

Tasrif Pharmaceutical Granted Second U.S. Patent for CD155-Targeting Antibody Developed with Abzena’s Humanization & Immunogenicity Platforms
Abzena’s Customer Promatix Awarded Innovate UK Biomedical Catalyst Grant to Advance Cis-Bispecific ADC
Liraglutide Combination Products Incorporating Stevanato Group's Alina® Pen Injector Received Marketing Authorizations in Multiple European Countries
Pace Life Sciences Announces Compliant US FDA Inspection of Operations in Research Triangle Park, NC

  EXPERT CONTENT & RESOURCES

 

Why Assembly and Packaging Have Become the Critical Path to Drug-Device Launch  

Why Assembly and Packaging Have Become the Critical Path to Drug-Device Launch  

The pharmaceutical industry has spent decades refining drug discovery, biologics manufacturing and fill-finish operations. However, for many combination products today, the greatest risk to launch timelines no longer sits upstream in formulation or production.

Vin Singh Bullfrog AI

BullFrog AI: Applying an End-to-end AI Workflow to Improve Clinical Development 

BullFrog AI Founder and CEO Vin Singh discusses how the company’s end-to-end AI workflow prepares complex clinical data, identifies disease drivers and patient subgroups, and turns those insights into explainable recommendations designed to improve clinical development decisions.

Nina Bauer

Why NAMs Took Decades to Arrive – and Why iPSCs are Making Them Possible

When US and European regulators acted in recent years to support the use of animal model alternatives for drug development, reactions were mixed. There is broad acknowledgement regarding the limitations of animal-based disease models and their inability to fully recapitulate human biological complexity, contributing to a high clinical failure rate, and so there was true excitement for the possibilities.

FDA QSMR Image

Navigating FDA QMSR in 2026 

For years, many medical device manufacturers approached FDA inspections through a familiar lens: prepare documents, review subsystem requirements, rehearse likely questions, and demonstrate compliance against a known framework.

  FEATURED EDITORIAL

  EXPERT INSIGHTS VIDEOS

Mastering Analytics: LC-MS Analysis of Oligonucleotide Drugs

Mastering Analytics: LC-MS Analysis of Oligonucleotide Drugs

  COMPANY PROFILE

Company Logo

You didn’t get into biotech to become a packaging expert. We did. 

Datwyler is a leading provider of high-quality, system-critical elastomer components. We materialize ideas for a safer, smarter and more sustainable world.

Leading Market Positions

As a high-tech company, we focus on pharmaceutical packaging and hold leading positions in attractive global markets such as Healthcare, Mobility, Connectivity, General Industry and Food & Beverage.

Click here for more.

  WHITEPAPERS & WEBINARS

WEBINAR ON DEMAND: Why early matters: Data-driven strategies to de-risk OSD development

WEBINAR ON DEMAND: Why early matters: Data-driven strategies to de-risk OSD development

Late-stage surprises continue to drive cost, delay, and challenges in oral solid dosage (OSD) development—especially for complex, poorly soluble molecules. Too often, formulation and manufacturability risks surface only after significant time and investment.

In a recent panel discussion, GlobalData’s Director …

WHITEPAPER - An Introduction to PLG Polymers for Long‑Acting Drug Delivery

WHITEPAPER - An Introduction to PLG Polymers for Long‑Acting Drug Delivery

Bioabsorbable poly(lactide-co‑glycolide) (PLG) polymers and poly(lactic acid-co-glycolic acid) (PLGA) have become an essential part of modern healthcare. Over the past five decades, these polymers have transformed how medicines are delivered – enabling long-acting injectables, implants, and localized drug‑delivery products …

WHITEPAPER - From Service Provider to Strategic Partner

WHITEPAPER - From Service Provider to Strategic Partner

By: Tom Sellig, CEO, Adare Pharma Solutions

As drug development grows more complex and timelines compress, sponsors require CDMO relationships built on integration, flexibility, and shared accountability. The relationship between pharmaceutical sponsors and their CDMO partners has undergone a fundamental …

  DRUG DEVELOPMENT DIRECT RESOURCES

Upcoming eNewsletter Features:

August 12 – Lyophilization Manufacturing
August 19 – Excipients
August 26 – Gene Therapy